Mount Gibson Iron Ltd. (FWQ)

Overview

Metagenomi, Inc. is a pioneering genetic medicines company based in Emeryville, California, focusing on the development of therapeutics for patients across the United States. Leveraging the power of metagenomics-derived genome editing tools, the company aims to revolutionize the treatment landscape for various diseases. Since its incorporation in 2016, Metagenomi has been at the forefront of integrating advanced genome editing technologies into therapeutic product development. The company is actively collaborating with other industry leaders such as Affini-T Therapeutics, Inc. and Ionis Pharmaceuticals, Inc., to expand the potential of genetic medicines in oncology and other areas requiring precise genomic alterations.

Products and Services

• Genome Editing Toolbox:

  Metagenomi's core offering includes an expansive set of genome editing technologies. These include programmable nucleases, which are enzymes designed to cut DNA at specific locations, enabling the modification or correction of genetic material. Base editors, a newer class of genome editing tools, allow for the direct conversion of one DNA base pair into another without inducing double-strand breaks, offering a more precise editing technique. Additionally, Metagenomi employs RNA and DNA-mediated integration systems such as prime editing systems and clustered regularly interspaced short palindromic repeat-associated transposases (CRISPR-associated transposases). These innovative technologies enable precise and efficient genomic insertions, deletions, and modifications, paving the way for groundbreaking treatments.

• Collaborative Therapeutic Development:

  Through its strategic partnerships, Metagenomi is actively working on the development and commercialization of gene-edited T-cell receptor-based therapeutic products for the treatment, prevention, and diagnosis of human cancers. This effort, in collaboration with Affini-T Therapeutics, Inc., signifies a major step toward harnessing the immune system's power to fight cancer with unmatched precision. In addition, the company's collaboration with Ionis Pharmaceuticals, Inc. focuses on researching, developing, and commercializing investigational medicines utilizing genome editing technologies. These partnerships underscore Metagenomi's commitment to advancing genetic medicine and providing novel therapies for unmet medical needs.